Biologická liečba monoklonovými protilátkami // SOLEN

Onkológia 2/2019

Biological treatment with monoclonal antibody

Biological medicinal products form an integral and effective part of the management of different diseases. They are crucial to treating life-threatening conditions in all medicine areas, including oncology. The killing of tumour cells using monoclonal antibodies (mAbs) can result from direct action of the antibody through receptor blockade, immune-mediated cell killing mechanisms, and specific effects of an antibody on the tumour vasculature and stroma. Tumour antigens that have been successfully targeted include epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), cytotoxic T lymphocyte-associated antigen 4 (CTLA4), CD20, CD30 and CD52. However, partial and transient responses, as well as emergence of tumour resistance, currently limit clinical application of mAbs. The question about biological medicinal products is the existential of biosimilars. More specifically, we inform aspects related to definition, forms of biosimilars, labelling, extrapolation, interchangeability, switching, automatic substitution, clinical standards on safety and efficacy, and potential impact on financial burden in healthcare.

Keywords: oncology, monoclonal antibodies, biosimilars